Source-grounded facts extracted from Processa Pharmaceuticals, Inc.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Sian Bigora changed role as Chief Development and Regulatory Officer at Processa Pharmaceuticals, Inc..
“On April 30, 2026, Processa Pharmaceuticals, Inc. (the “Company”) approved a transition in the employment status of Dr. Sian Bigora, the Company’s Chief Development and Regulatory Officer, as part of her planned transition toward retirement.”
Processa Pharmaceuticals, Inc. terminated Binding Term Sheet with Intact Therapeutics valued at Term Sheet expired without execution of definitive license agreement (effective 2026-02-12).
“On February 12, 2026, Processa Pharmaceuticals, Inc.’s (the “Company”) Binding Term Sheet dated June 17, 2025 (the “Term Sheet”) with Intact Therapeutics regarding PCS12852 expired without the execution of a definitive license agreement and without the entry into the related proposed amendment to the License Agreement with Yuhan Corporation.”
Processa Pharmaceuticals, Inc.: Processa Pharmaceuticals filed a Certificate of Amendment to effect a 1-for-25 reverse stock split of common stock (effective 2025-12-16).
“On December 12, 2025, Processa Pharmaceuticals, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Fourth Amended and Restated Certificate of Incorporation to effect a 1-for-25 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”), effective as of 5:00 p.m. Eastern Time on December 16, 2025.”
Processa Pharmaceuticals, Inc.: The Company filed an amendment to its Fourth Amended and Restated Certificate of Incorporation to increase authorized common stock from 100,000,000 shares to 1,000,000,000 shares (effective 2025-09-12).
“Effective September 12, 2025, Processa Pharmaceuticals, Inc. (the “Company” or “us” or “we”) filed an amendment to its Fourth Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to increase the number of authorized shares of common stock from 100,000,000 shares to 1,000,000,000 shares (the “Amendment”).”
Processa Pharmaceuticals, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“August 7, 2025, the Company received a letter from the Staff notifying that the Company is eligible for a second 180-day period, or until February 2, 2026 (the “Second Grace Period”) to regain compliance with the Bid Price Requirement. According to the notification from Nasdaq, the Staff’s determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held shares and all other Nasdaq initial listing standards, with the exception of the minimum bid price requirement, and (ii) the Company’s written notice to Nasdaq of its intention to cure t”
Processa Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“February 4, 2025, Processa Pharmaceuticals, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). The Notice has no effect at this time on the Company’s common stock, which continues to trade on The Nasdaq”
Processa Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“February 4, 2025, Processa Pharmaceuticals, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company t”
Processa Pharmaceuticals, Inc. engaged Cherry Bekaert LLP as its auditor.
“On November 6, 2024, the Audit Committee approved the engagement of Cherry Bekaert LLP ("Cherry Bekaert") as its new independent registered public accounting firm.”
BD & Company., Inc. resigned as auditor of Processa Pharmaceuticals, Inc..
“On October 31, 2024, BD & Company., Inc. ("BD & Co") merged in Citrin Cooperman and resigned as the Company’s independent registered public accounting firm.”
James Stanker resigned as Chief Financial Officer at Processa Pharmaceuticals, Inc..
“by mutual agreement, James Stanker resigned as Chief Financial Officer of the Company, effective July 15, 2024.”
Russell Skibsted was appointed as Chief Financial Officer at Processa Pharmaceuticals, Inc..
“announced the appointment of Mr. Russell Skibsted, Effective July 16, 2024 as its Chief Financial Officer.”
Processa Pharmaceuticals, Inc. entered into Securities Purchase Agreement with certain institutional investors valued at approximately $7.0 million (effective 2024-01-26).
“On January 26, 2024, Processa Pharmaceuticals, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) with certain institutional investors, pursuant to which the Company agreed to sell and issue, in a registered public offering (the “Offering”), (i) 476,000 shares (the “Shares”) of the Company’s common stock, par value $0.0001 per share (the “common stock”), (ii) warrants to purchase 1,555,555 shares of common stock (the “Common Warrants”) and (iii) pre-funded warrants to purchase up to 1,079,555 shares of common stock in lieu of shares of common stock (the “Pre-Funded Warrants”).”
Processa Pharmaceuticals, Inc.: Certificate of Amendment to Fourth Amended and Restated Certificate of Incorporation to effect a 1-for-20 reverse stock split (effective 2024-01-22).
“On January 18, 2024, Processa Pharmaceuticals, Inc. (the “Company”) filed with the Secretary of State of the State of Delaware a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Fourth Amended and Restated Certificate of Incorporation to effect a 1-for-20 reverse stock split (the “Reverse Stock Split”) of the Company’s issued and outstanding shares of common stock, par value $0.0001 per share (the “Common Stock”), effective as of 12:01 a.m. Eastern Time on January 22, 2024.”
Processa Pharmaceuticals, Inc. shareholders approved grant the Board of Directors discretionary authority to amend the Company’s Fourth Amended and Restated Certificate of Incorporation to effect a reverse stock split of the Company’s outstanding common stock, $0.0001 par value per share, at a ratio of not less than 1-for-5 and not more than 1-for-30 at the 2023-11-14 meeting.
“Non-Vote 13,895,377 1,341,351 21,455 - Proposal 2: Adjournment Proposal Shares For Against Abstain Broker”
Virgil Thompson departed as Member of the Board of Directors and Chairman of Nominating and Governance Committee at Processa Pharmaceuticals, Inc..
“announcing that Virgil Thompson, age 83, a member of the Company’s Board of Directors and Chairman of our Nominating and Governance Committee, unexpectedly passed away on Thursday November 9, 2023.”
Processa Pharmaceuticals, Inc.: Amended and Restated Bylaws adopted, changing vote standard for routine matters to majority of votes cast, permitting stockholder action by written consent, modifying director removal to for-cause only with 66% vote, changing director count and vacancy procedures, removing indemnification exceptions (effective 2023-09-18).
“On September 18, 2023, the Board of Directors (the “Board”) of the Company adopted the Amended and Restated Bylaws (as amended, the “Bylaws”).”
Processa Pharmaceuticals, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“September 19, 2023, the Company received a letter from the Staff notifying that the Company is eligible for a second 180-day period, or until March 18, 2024 (the “Second Grace Period”) to regain compliance with the Bid Price Requirement. According to the notification from Nasdaq, the Staff’s determination was based on (i) the Company meeting the continued listing requirement for market value of its publicly held shares and all other Nasdaq initial listing standards, with the exception of the minimum bid price requirement, and (ii) the Company’s written notice to Nasdaq of its intention to cure”
Processa Pharmaceuticals, Inc. received a nasdaq noncompliance notice notice regarding minimum bid price (rules 5550(a)(2)).
“March 22, 2023, Processa Pharmaceuticals, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). On September 19, 2023, the Company received a letter from the Staff notifying that the Company is eligible fo”
R. Michael Floyd resigned as Chief Operating Officer at Processa Pharmaceuticals, Inc..
“Mr. R. Michael Floyd resigned as Chief Operating Officer of the Company, effective August 31, 2023.”
David Young changed role as President of Research and Development at Processa Pharmaceuticals, Inc..
“Dr. David Young will continue with the Company as a member of the Board of Directors and as the Company’s President of Research and Development.”
George Ng was appointed as director at Processa Pharmaceuticals, Inc..
“announced the appointment of Mr. George Ng as its Chief Executive Officer and a director.”
George Ng was appointed as Chief Executive Officer at Processa Pharmaceuticals, Inc..
“announced the appointment of Mr. George Ng as its Chief Executive Officer and a director.”
Processa Pharmaceuticals, Inc.: Increased authorized shares of common stock from 50,000,000 to 100,000,000 (effective 2023-06-27).
“Effective June 27, 2023, Processa Pharmaceuticals, Inc. (the “Company” or “us” or “we”) filed an amendment to its Fourth Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware to increase the number of authorized shares of common stock from 50,000,000 shares to 100,000,000 shares (the “Amendment”).”
Processa Pharmaceuticals, Inc. shareholders approved Advisory vote relating to compensation of our named executive officers at the 2023-06-27 meeting.
“4. Results of the advisory vote relating to compensation of our named executive officers were as follows: Shares For Against Abstain Broker Non-Vote 9,724,358 1,916,645 89,523 2,477,214”
Processa Pharmaceuticals, Inc. shareholders approved Ratification of the appointment of BD & Company, Inc. as the independent registered public accounting firm for 2023 at the 2023-06-27 meeting.
“3. The appointment of BD & Company, Inc. as the independent registered public accounting firm for 2023 was ratified based on the following votes: Shares For Against Abstain Broker Non-Vote 12,862,749 398,544 946,447 -”
Processa Pharmaceuticals, Inc. shareholders approved Amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 50,000,000 shares to 100,000,000 shares at the 2023-06-27 meeting.
“2. The amendment to the Company’s Fourth Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 50,000,000 shares to 100,000,000 shares. The votes cast were as follows: Shares For Against Abstain Broker Non-Vote 12,430,395 1,736,546 40,799 -”
Processa Pharmaceuticals, Inc. shareholders approved Election of all six directors to serve until the next Annual Meeting of Shareholders or until their successors have been duly elected and qualified at the 2023-06-27 meeting.
“1. The election of all six directors to serve until the next Annual Meeting of Shareholders or until their successors have been duly elected and qualified based on the following votes: Shares Name For Against Abstain Broker Non-Votes Justin Yorke 10,850,801 - 879,725 2,477,214 Dr. David Young 9,973,718 - 1,756,808 2,477,214 Khoso Baluch 10,909,404 - 821,122 2,477,214 James Neal 10,899,404 - 831,122 2,477,214 Geraldine Pannu 9,817,229 - 1,913,297 2,477,214 Virgil Thompson 10,226,498 - 1,504,028 2,477,214”
Processa Pharmaceuticals, Inc. reported year ended December 31, 2022 results: net income $27.4 million, or $1.70 per share, EPS $1.70 per share.
“Our net loss for the year ended December 31, 2022 was $27.4 million, or $1.70 per share, compared to a net loss of $11.4 million, or $0.75 per share for the same period of 2021.”
Processa Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“March 22, 2023, Processa Pharmaceuticals, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). The Notice has no effect at this time on the Company’s common stock, which continues to trade on The Nasdaq C”
Processa Pharmaceuticals, Inc. entered into Purchase Agreement with certain accredited investors valued at approximately $6.25 million (effective 2023-02-09).
“On February 9, 2023, Processa Pharmaceuticals, Inc. (the “Company”) and certain accredited investors (the “Investors”) entered into a securities purchase agreement (the “Purchase Agreement”) relating to the issuance and sale of shares of common stock pursuant to a registered direct offering (the “Offering”).”
Processa Pharmaceuticals, Inc. reported for the nine months ended September 30, 2022 results: net income $14.4 million, EPS $0.90 per share.
“Our net loss for the nine months ended September 30, 2022, was $14.4 million or $0.90 per share”
James R. Neal was appointed as Board of Directors at Processa Pharmaceuticals, Inc..
“On July 19, 2022, the Board of Directors of Processa Pharmaceuticals, Inc. (the “Company”) appointed James R. Neal to its Board of Directors, effective immediately.”
Khalid Islam retired as member of the Board of Directors at Processa Pharmaceuticals, Inc..
“Dr. Khalid Islam, who served as a member of the Board of Directors of the Company (the “Board”) since November 2020, retired from the Board Company effective as of the Annual Meeting.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.